APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024
Most Cited Paper
in Hepatocellular Carcinoma Treatment and Prognosis
18 Months Post-Publication
Class of 2026
“APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/hepatocellular-carcinoma-treatment-and-prognosis/2026/
Topics
Hepatocellular carcinoma · Systemic therapy · Clinical practice guidelines · APASL · sorafenib · lenvatinib · Atezolizumab plus bevacizumab · Durvalumab plus tremelimumab · Immune checkpoint inhibitor therapy · Tyrosine kinase inhibitor · First-line treatment · Second-line therapy · Barcelona Clinic Liver Cancer (BCLC) staging · Child-Pugh class · Overall survival · Progression-free survival · Objective response rate · Hepatitis B virus infection · Hepatitis C virus infection · Cirrhosis · regorafenib · cabozantinib · ramucirumab · nivolumab · pembrolizumab · VEGF signaling pathway · PD-L1 expression · biomarker selection · combination immunotherapy · Adverse event management
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Hepatocellular Carcinoma Treatment and Prognosis Papers, Class of 2026. https://pri.pepkio.com/top-papers/hepatocellular-carcinoma-treatment-and-prognosis/2026. Accessed 2026-07-13. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459